FEB 2 0 2001 ttorney's Docket No. 35800/204489(5800-28A) GAU 1655 Box Seq.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Robison et al.

Appl. No.:

09/668,266

September 22, 2000

Group Art Unit: 1655

FEB 2 2 2001

Filed: For:

22025, A NOVEL HUMAN CYCLIC NUCLEOTIDE

Examiner: B. Sisson

RECEIVED

PHOSPHODIESTERASE

TECH CENTER 1600/2900

February 12, 2001

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PA APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated January 10, 2001 Applicant herewith submits an initial sequence listing and the computerreadable form of the sequence listing.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted concurrently herewith in accordance with 37 CFR § 1.821(c) and (e), are the same.

Respectfully submitted,

Kathyn L. Coult

Kathryn L. Coulter

Agent for Applicant

Registration No. 45,889

ALSTON & BIRD LLP

Post Office Drawer 34009 Charlotte, NC 28234 Tel Raleigh Office (919) 420-2200 Fax Raleigh Office (919) 420-2260 CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on February 12, 2001.

lsra Nora C. Martinez

RTA01/2091136v1

Application	No.	091668266

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

not con	cleotide and/or amino acid sequencePdraclosure contained in this application does apply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - for the following reason(s):
	1. This application clearly rails to comply with the requirements of 37 CFR 1.821-
	1. This application clearly tails to comply with one department of the series of the s
	29, May 13, 1990 and do 50 to
M	2. This application does not contain, as a separate part of the disclosure on
	paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
N	3. A copy of the "Sequence Listing" in computer readable form has not been
	submitted as required by 37 CFR 1.821(e).
	en de la companya de La companya de la co
	4. A copy of the "Sequence Listing" in computer readable form has been submitted.
	However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required
	by 37 CFR 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer
	readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
\Box	
لــا	7. Other:
Appl	icant must provide:
	An initial or substitute computer readable form (CRF) copy of the "Secretarian computer readable for t
\Box	Listing"
	An initial or substitute paper copy of the "Sequence Listing", as well as an
<u></u> /	amendment directing its entry into the specification
	A statement that the content of the paper and computer readable copies are the sar
	and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
	questions regarding compliance with these requirements, please contac
For	Rules Interpretation, call (703) 308-1123 CRF submission help, call (703) 308-4212 PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.